CD4 and neoplasm: Recently, we compared zirconium-89 (89Zr)–labeled human and mouse CD4-specific minibodies in different syngeneic tumor models and successfully identified responders to combined αPD-L1/αLAG-3 ICI therapy in an MC38 tumor mouse model based on the whole-tumor PET uptake (30).